Cambridge, United Kingdom
Enhanced Genomics, established in 2020, is a pioneering force in the Biotechnology sector, anchored in the United Kingdom. The company's focus, articulated through its slogan, "Transforming therapeutic development through functional genomics," is on redefining therapeutic discovery with innovative technology.
Their cutting-edge platform develops high-resolution profiles of 3D genome folding, offering insights that connect gene enhancers and non-coding genetic variants to their associated genes. This capability positions Enhanced Genomics at the forefront of therapeutic discovery, a field ripe for scientific and market breakthroughs.
Rooted in research as a spinout from the Babraham Institute, the company benefits from academic prowess in regulatory genomics. Its recent fundraising success, a £10.00M Series A investment in October 2022, includes backing from prestigious investors like Parkwalk Advisors, Bioqube Ventures, and the Business Growth Fund, illustrating robust investor confidence and significant growth potential.
